Cargando…

Emerging role of GLP-1 receptor agonists in the treatment of obesity

The prevalence of obesity has increased dramatically in recent decades, both in the US and worldwide. Pharmacotherapy can augment the weight-reducing effects of lifestyle modification and can facilitate long-term weight maintenance. However, there is a paucity of pharmacologic agents approved for th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neff, Lisa M, Kushner, Robert F
Formato:	Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047971/ https://www.ncbi.nlm.nih.gov/pubmed/21437094

Ejemplares similares

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
por: Wang, Jing-Yue, et al.
Publicado: (2023)

The Role of Glp-1 Receptor Agonists in Insulin Resistance with Concomitant Obesity Treatment in Polycystic Ovary Syndrome
por: Bednarz, Krzysztof, et al.
Publicado: (2022)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
por: Popoviciu, Mihaela-Simona, et al.
Publicado: (2023)

Role and development of GLP-1 receptor agonists in the management of diabetes
por: Chia, Chee W, et al.
Publicado: (2009)

Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment
por: Trapp, Stefan, et al.
Publicado: (2021)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

GLP-1 Receptor Agonists and Kidney Protection
por: Greco, Eulalia Valentina, et al.
Publicado: (2019)

The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction
por: Rizvi, Ali A, et al.
Publicado: (2022)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

FRI064 The Role Of GLP-1 Receptor Agonists In The Treatment Of Pituitary And Hypothalamic Tumor Induced Obesity
por: Botero Suarez, Carlos S, et al.
Publicado: (2023)

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
por: Ja’arah, Daria, et al.
Publicado: (2021)

Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
por: Madsen, Mette Simone Aae, et al.
Publicado: (2019)

Targeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists
por: Ghosh, Puja, et al.
Publicado: (2023)

What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?
por: Holst, Jens Juul
Publicado: (2021)

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
por: Nauck, Michael A., et al.
Publicado: (2020)

GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight
por: Monti, Giulia, et al.
Publicado: (2022)

GLP-1/glucagon receptor co-agonism for treatment of obesity
por: Sánchez-Garrido, Miguel A., et al.
Publicado: (2017)

Energy Balance in Hypothalamic Obesity in Response to Treatment with a Once-Weekly GLP-1 Receptor Agonist
por: Shoemaker, Ashley H., et al.
Publicado: (2022)

GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
por: Lee, Jinmi, et al.
Publicado: (2012)

Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
por: Miñambres, Inka, et al.
Publicado: (2017)

GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective
por: Rasalam, Roy, et al.
Publicado: (2019)

Novel Insights into the Roles and Mechanisms of GLP-1 Receptor Agonists against Aging-Related Diseases
por: Peng, Wei, et al.
Publicado: (2022)

Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
por: Saraiva, Francisco Kerr, et al.
Publicado: (2014)

Basal Insulin Use With GLP-1 Receptor Agonists
por: Anderson, Sarah L., et al.
Publicado: (2016)

GLP-1 receptor agonists: an updated review of head-to-head clinical studies
por: Trujillo, Jennifer M., et al.
Publicado: (2021)

Nephroprotective effects of GLP-1 receptor agonists: where do we stand?
por: Mosterd, Charlotte M., et al.
Publicado: (2020)

The use of GLP‐1 receptor agonists in hospitalised patients: An untapped potential
por: Mustafa, Omar G., et al.
Publicado: (2019)

The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
por: Du, Haiyang, et al.
Publicado: (2022)

Emerging Nondopaminergic Medications for Parkinson’s Disease: Focusing on A(2A) Receptor Antagonists and GLP1 Receptor Agonists
por: Shang, Pei, et al.
Publicado: (2021)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021)

Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations
por: Xu, Dan, et al.
Publicado: (2022)

Dual GIP–GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential
por: Bastin, Marie, et al.
Publicado: (2019)

GLP-1 Receptor Agonists: Nonglycemic Clinical Effects in Weight Loss and Beyond
por: Ryan, Donna, et al.
Publicado: (2015)

Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
por: Wang, Qinghua, et al.
Publicado: (2010)

Targeting GLP-1 receptor trafficking to improve agonist efficacy
por: Jones, Ben, et al.
Publicado: (2018)

The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases
por: Cheng, Dihe, et al.
Publicado: (2022)

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
por: Gallwitz, Baptist
Publicado: (2022)

Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications
por: Unger, Jeffrey R., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_4aledd4961n6d0h4ent4m4f9fo